Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab +/- Tremelimumab plus Chemotherapy in mNSCLC-MedSci.cn

Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab +/- Tremelimumab plus Chemotherapy in mNSCLC

Peters, S; Cho, BC; Luft, A; Alatorre-Alexander, J; Geater, SL; Kim, SW; Ursol, G; Hussein, M; Lim, FL; Yang, CT; Araujo, LH; Saito, H; Reinmuth, N; Stewart, R; Lai, Z; Doake, R; Krug, L; Garon, EB; Mok, T; Johnson, ML

JOURNAL OF THORACIC ONCOLOGY, 2022; 17 (9): S39

科室
- - 订阅+
  - 更多科室
工具
服务